Results from preclinical studies forecast great promise for inhibitors of EZH2 catalysis as treatment for such genetically defined cancers [18], [19], [20], [21], [22], and EZH2 inhibitors may also mitigate chemotherapy resistance. The gene discussed is EZH2; the disease is cancer.